Atom Investors’s Bicara Therapeutics BCAX Stock Holding History

Atom Investors’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-55,141	Closed	-$512K	–	869
2025 Q2	$512K	Buy	+55,141	New	+$657K	0.05%	350

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atom Investors's BCAX Position: Q3 2025 in Review

Atom Investors sold out of Bicara Therapeutics (BCAX) in Q3 2025, closing a stake of 55,141 shares — an estimated $512K sold.

Atom Investors first reported a position in BCAX in Q2 2025 and held it in 1 quarter. The position peaked at $512K in Q2 2025. 114 funds tracked by Wall St. Rank hold BCAX as of Q3 2025.

Atom Investors reported no remaining Bicara Therapeutics position as of Q3 2025 after selling out during the quarter.
Atom Investors sold 55,141 Bicara Therapeutics shares in Q3 2025, an estimated $512K.
Atom Investors first reported a position in Bicara Therapeutics in Q2 2025 and held it in 1 quarter.
Atom Investors's Bicara Therapeutics position peaked at $512K in Q2 2025.
114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2025.

Based on Atom Investors's 13F filing for Q3 2025, filed 14 Nov 2025.